1. Home
  2. CASH vs SNDX Comparison

CASH vs SNDX Comparison

Compare CASH & SNDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Pathward Financial Inc.

CASH

Pathward Financial Inc.

HOLD

Current Price

$73.81

Market Cap

1.5B

Sector

Finance

ML Signal

HOLD

Logo Syndax Pharmaceuticals Inc.

SNDX

Syndax Pharmaceuticals Inc.

BUY

Current Price

$13.20

Market Cap

1.6B

Sector

Health Care

ML Signal

BUY

Company Overview

Basic Information
Metric
CASH
SNDX
Founded
1954
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.5B
1.6B
IPO Year
1996
2014

Fundamental Metrics

Financial Performance
Metric
CASH
SNDX
Price
$73.81
$13.20
Analyst Decision
Buy
Strong Buy
Analyst Count
3
12
Target Price
★ $97.50
$37.27
AVG Volume (30 Days)
178.9K
★ 1.9M
Earning Date
10-21-2026
11-02-2026
Dividend Yield
★ 0.28%
N/A
EPS Growth
N/A
★ 11.56
EPS
★ 6.29
N/A
Revenue
★ $839,894,000.00
$172,352,000.00
Revenue This Year
N/A
$82.25
Revenue Next Year
$5.62
$46.17
P/E Ratio
$11.48
★ N/A
Revenue Growth
11.29
★ 627.84
52 Week Low
$65.93
$12.80
52 Week High
$101.26
$25.59

Technical Indicators

Market Signals
Indicator
CASH
SNDX
Relative Strength Index (RSI) 40.46 21.89
Support Level $70.60 N/A
Resistance Level $75.72 $18.75
Average True Range (ATR) 1.51 0.73
MACD 0.38 -0.43
Stochastic Oscillator 38.64 4.31

Price Performance

Historical Comparison
CASH
SNDX

About CASH Pathward Financial Inc.

Pathward Financial Inc is a unitary savings and loan holding company. It's a wholly owned full-service banking subsidiary of Meta Financial, is both a community-oriented financial institution offering a variety of financial services to meet the needs of the communities it serves, and a payments company providing services on a nationwide basis. It operates through three reportable segments: Consumer: The Consumer segment includes the Partner Solutions business line, which collaborates with partners to navigate payment and lending needs; Commercial: The Commercial segment includes the Company's Commercial Finance business line, which helps businesses access funds needed to launch, operate, and grow; and Corporate Services. The majority of the revenue is generated from Consumer segment.

About SNDX Syndax Pharmaceuticals Inc.

Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.

Share on Social Networks: